Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 7,057 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer, Breast Neoplasms Clear all
Completed Phase 2 Interventional Results available

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

NCT00903162
View directory record Official record
Conditions
Breast Cancer
Interventions
leuprolide, letrozole, zoledronic acid
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Denver, Colorado • Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutrition, Exercise, and Breast Cancer Survivorship

NCT01151488
View directory record Official record
Conditions
Breast Cancer Survivorship, Sarcopenia
Interventions
Resistance Training
Other
Lead sponsor
Baltimore VA Medical Center
Federal
Eligibility
45 Years to 80 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Not applicable Interventional Results available

A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy

NCT01624220
View directory record Official record
Conditions
Spinal Tumor
Interventions
Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation, Questionnaires
Radiation · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

NCT00304096
View directory record Official record
Conditions
Breast Cancer
Interventions
synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 2 Interventional

Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00049062
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, gefitinib
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 25, 2026, 7:00 AM EDT
Terminated Phase 2 Interventional Results available

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

NCT03872388
View directory record Official record
Conditions
Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Atorvastatin, Capecitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Gilbert, Arizona • Greeley, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 25, 2026, 7:00 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

NCT03729115
View directory record Official record
Conditions
Breast Cancer
Interventions
Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
25 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
3
States / cities
La Jolla, California • Sacramento, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 25, 2026, 7:00 AM EDT
Recruiting Phase 1Phase 2 Interventional

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

NCT05735080
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
Interventions
INX-315, Fulvestrant, Abemaciclib
Drug
Lead sponsor
Incyclix Bio
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Orlando, Florida • Atlanta, Georgia • Augusta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 25, 2026, 7:00 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Onvansertib + Paclitaxel In TNBC

NCT05383196
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Inflammatory Breast Cancer, Triple Negative Breast Cancer (TNBC), Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions
Onvansertib, Paclitaxel
Drug
Lead sponsor
Antonio Giordano, MD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 25, 2026, 7:00 AM EDT
Active, not recruiting Phase 2 Interventional

Trial to Compare Radiation Fibrosis With Five Versus Three Fractions

NCT02755896
View directory record Official record
Conditions
Malignant Neoplasm of Breast Stage I
Interventions
Arm 1 600 cGY x 5 fractions, Arm 2 800 cGY x 3 fractions
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
4
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 25, 2026, 7:00 AM EDT
Recruiting Not applicable Interventional

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

NCT07066189
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Exercise and Medical Nutrition
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Early Phase 1 Interventional

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

NCT01467310
View directory record Official record
Conditions
Breast Cancer
Interventions
GSK1120212
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 2 Interventional

Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer

NCT00006682
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, vinorelbine ditartrate
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 3 Interventional Results available

Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer

NCT00343382
View directory record Official record
Conditions
Breast Cancer, Vaginal Dryness
Interventions
pilocarpine hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
192
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 123 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 25, 2026, 7:00 AM EDT
Completed No phase listed Observational

Cancer Genetics Hereditary Cancer Panel Testing

NCT02324062
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer
Interventions
Questionnaires, Blood Draw and Baseline Questionnaire
Other
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
1,511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Los Angeles, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 25, 2026, 7:00 AM EDT
Terminated Phase 2 Interventional Results available

Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer

NCT00777335
View directory record Official record
Conditions
Breast Cancer
Interventions
Panobinostat - LBH589
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 25, 2026, 7:00 AM EDT
Recruiting Phase 2 Interventional

A Study of Romosozumab in People With Breast Cancer and Osteoporosis

NCT07776613
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer (MBC)
Interventions
Romosozumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 25, 2026, 7:00 AM EDT
Recruiting Phase 1 Interventional

A Study of LY4175408 in Participants With Advanced Cancer

NCT07046923
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer
Interventions
LY4175408, Pembrolizumab, Carboplatin, Cisplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
15
States / cities
Stanford, California • Orlando, Florida • Sarasota, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 25, 2026, 7:00 AM EDT
Active, not recruiting No phase listed Observational

An Ophthalmic Safety Study in Patients With Breast Cancer

NCT06767462
View directory record Official record
Conditions
Ophthalmic Safety in Patients With Breast Cancer
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
La Jolla, California • Palo Alto, California • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Not applicable Interventional

Preoperative Accelerated Partial Breast Irradiation (APBI) for Women With Stage I and Select IIA Breast Cancer

NCT01014715
View directory record Official record
Conditions
Breast Cancer
Interventions
Phase II - Preoperative Radiation followed by Lumpectomy.
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Columbia, Maryland • Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Phase 2 Interventional

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

NCT02725489
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer, Cervical Cancer, Endometrial Cancer
Interventions
Vigil, Durvalumab
Biological · Drug
Lead sponsor
Mary Crowley Medical Research Center
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 25, 2026, 7:00 AM EDT
Withdrawn Not applicable Interventional

Evaluation of Perforator Phase Contrast Angiography in Developing Surgery Plans for Patients With Breast Cancer Undergoing Breast Reconstruction With Free-Flap Methods After Mastectomy

NCT04063410
View directory record Official record
Conditions
Mammoplasty Patient
Interventions
Angiography, MRI-Based Angiogram, Quality-of-Life Assessment
Procedure · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 25, 2026, 7:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS)

NCT03775213
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Decision Support Tool with Active Monitoring, Decision Support Tool without Active Monitoring
Behavioral
Lead sponsor
Duke University
Other
Eligibility
50 Years to 79 Years · Female only
Enrollment
322 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 25, 2026, 7:00 AM EDT
Terminated Not applicable Interventional Results available

Depocyt® With Sorafenib in Neoplastic Meningitis

NCT00964743
View directory record Official record
Conditions
Neoplastic Meningitis
Interventions
DepoCyt, Sorafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Oct 25, 2026, 7:00 AM EDT